TerminatedNCT03577899
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
PHASE3 · 1,157 planned enrolment
- Countries listed
- 22
- Registry update
- June 24, 2021
immortal.lifeTrial registrations containing the exact intervention label 1.0 mg Conbercept Intravitreal Injection.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 1,157 planned enrolment
PHASE3 · 1,157 planned enrolment